Currently, there are 23.69M common shares owned by the public and among those 22.28M shares have been available to trade.
The company’s stock has a 5-day price change of -5.71% and 6.01% over the past three months. VBIV shares are trading 12.34% year to date (YTD), with the 12-month market performance down to -83.93% lower. It has a 12-month low price of $0.45 and touched a high of $5.82 over the same period. VBIV has an average intraday trading volume of 282.55K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.49%, 5.55%, and -23.37% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of VBI Vaccines Inc. (NASDAQ: VBIV) shares accounts for 12.26% of the company’s 23.69M shares outstanding.
It has a market capitalization of $15.64M and a beta (3y monthly) value of 1.84. The earnings-per-share (ttm) stands at -$11.87. Price movements for the stock have been influenced by the stock’s volatility, which stands at 38.35% over the week and 14.48% over the month.
Analysts forecast that VBI Vaccines Inc. (VBIV) will achieve an EPS of -$0.22 for the current quarter, -$0.17 for the next quarter and -$0.82 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.22 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$0.08 a year ago.
Looking at the support for the VBIV, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on November 11, 2022, with the firm’s price target at $5-$2. Jefferies coverage for the VBI Vaccines Inc. (VBIV) stock in a research note released on December 29, 2021 offered a Buy rating with a price target of $6. Jefferies was of a view on February 25, 2021 that the stock is Buy, while Raymond James gave the stock Strong Buy rating on August 27, 2020, issuing a price target of $8- $9. Oppenheimer on their part issued Outperform rating on January 16, 2019.
